Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-10
2026-525919-14-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing Eloralintide once weekly with Placebo once weekly (2 arms). Primary endpoints: Percent change from baseline in body weight and Change from baseline in hemoglobin A1c. Planned start Oct 2026; status: authorised.
02
Drugs
eloralintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2026-525919-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525919-14-00.